Presenter: Dr. Andrew Hill, Senior Research Fellow, Department of Pharmacology and Therapeutics, Liverpool University, United Kingdom
Describtion: New HCV drugs, called direct-acting antivirals (DAAs), are too expensive. Generic DAAs will be key to provide universal access to treatment for millions of people with hepatitis C, espcially in low- and middle-income countries (LMICs). In this webinar, Dr. Andrew Hill presents his team's research to show how Generic DAAs can be produced for a fraction of the market price.
About the presenter: Dr. Andrew Hill graduated from Oxford University, with a PhD from the University of Amsterdam. He has been working on HIV and HCV drug development for over 20 years and now specializes in treatment access. His work has been published in many different medical journals including Science, the Lancet, Clinical Infectious Diseases, and Hepatology. He works as an advisor to the World Health Organization and the Clinton Health Access Initiative.